Date: July 19-23, 2021 Online Livestream Event Change is inevitable. More often than not, it demands learning new tools and technologies or even adopting new strategies. This takes time and resources but can be a lot easier if one has a team around to walk them through the rebuilding process. The 2021 Talent Acquisition Week is explicitly designed for that. It seeks to bring together the talent acquisition (“TA”) community and offer a platform where members can share best practices, tools, and innovative strategies to facilitate cumulative growth. Additionally, the Talent Acquisition week offers a way for those within the TA community to network, exchange ideas, and learn something that will take their TA playbook to the next level. This five-day event scheduled for July 19 to 23, 2021, will provide an unmatched deep dive into talent acquisition, touching on topics such as leveraging data while making hiring decisions to analytics and the fundamentals of talent acquisition in the modern age. The objective is to empower attendees and impact them with innovative tools, strategies, and technologies that will redefine talent attraction and acquisition. Some of the other topics that will be discussed include:

• Utilize Data to Ensure Strategic Talent Acquisition Decision Making
• Navigate the Post-Pandemic Hiring Market with Your Talent Data
• Leverage Digital Transformation to Drive Your Talent Acquisition Strategy
• Making Career Sites Work Better for People
• Humanizing the Candidate Experience

The event will have over 50 speakers from leading brands and organizations in the TA space, including Salesforce, Microsoft, Doordash, and PetSmart. With such a lineup, the event is guaranteed to spark healthy conversations and facilitate meaningful engagements that will help attendees take their talent acquisition playbook to the next level. The event will kick off with the emcee’s opening remarks, Andrew Gadomski, Managing Director, ASPEN Analytics, followed by Susan LaMotte, the CEO and Principal Strategist at Exaqueo. Susan will share her views on talent acquisition, highlighting the fundamentals therein, along with what attendees and those in the TA space need to know. The Talent Acquisition Week is the leading industry event specifically devoted to this topic. With a broad range of speakers and over 50 sessions, attendees are guaranteed to draw value, unmatched interaction, and engagement that will help improve their talent acquisition skills and playbook. For more information about the event and how to register, please visit https://ibn.fm/yv8XN.

• Staying connected to retail investors is critical in today’s market, considering retailers poured almost $28 billion into the stock market in June
• SRAX offers suite of products designed to improve due diligence, transparency, and communications between investors, corporations
• SRAX’s Sequire platform was expanded by implementing machine learning and other technology to add unlimited texting and emailing, custom filtering, performance metrics
• SRAX launched Microcaps.com, an editorial content and curated news distribution site catering to the growing Sequire investor community while providing small and microcap companies additional exposure

For the longest time, the communication structure between companies and investors was stale, comprised mostly of standard press releases for the masses. The outset of the digital world changed that to a degree, but it took innovation from companies like SRAX (NASDAQ: SRAX) to amp up the way the C-suite and investors interact. SRAX, a financial technology company, or “fintech,” specializes in the investment industry, providing products for investors and companies alike—a portfolio of offerings that got a little bigger in recent weeks. Notably, SRAX unlocks data and insights for publicly traded companies through Sequire, its SaaS platform. Through Sequire, companies can monitor trading data in real time, recognize shareholder buying and selling trends via data sets, track warrants, engage shareholders, and more from a single platform. Millions of retail investors have become increasingly self-directed, including pouring almost $28 billion into the stock market in June, the biggest inflow in about seven years (https://ibn.fm/dx91T). To that point, companies can use Sequire to put a finger on trading activity, as well as remain in contact with shareholders ranging from the biggest institution to the smallest retailer. The company recently released two new Sequire features: an automated email feature and an SMS function for communicating with investors. The additions include automation triggers, machine learning and other enhancements that facilitate frictionless communication while enabling the company to prepare contact lists in advance, customize messages to specific audiences, schedule updates and subsequently measure audience engagement via performance metrics. Companies can use custom filters (i.e., threshold of number of shares owned) to structure campaigns without concern for limitations. Users can send an unlimited number of texts to local and international numbers to engage and re-engage contacts. This is no small nuance considering the Sequire platform includes more than five million active retail investors and over 180 companies (https://ibn.fm/6cBli). “These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,” said SRAX Founder and CEO Christopher Miglino in a press release on the new features (https://ibn.fm/mmjBq). Only days later, SRAX launched Microcaps.com, an editorial content and curated news distribution site (https://ibn.fm/CBinX), dedicated to providing increased exposure and awareness for companies, in addition to information, news, and resources for small and microcap investors. More precisely, Microcaps.com was launched to benefit the growing Sequire investor community, serving as an information hub and interactive environment for the network. In addition to news and investor-facing articles, the website also includes links to presentations from Sequire virtual conferences. “We are creating this website to serve the entire microcap community,” said Christopher Miglino. “We are committed to building products that enhance exposure for public companies, and microcaps.com is a great example of the new tools we’re creating to gain more exposure for public issuers,” he added. More exposure is exactly what most public issuers, particularly small and microcaps, crave, as it is easy to get overlooked in markets containing thousands of other public companies. Many of these companies have big marketing budgets to stay in the forefront of investors, a disparity that SRAX is helping to level with its suite of assets. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Soil depletion causing mineral loss in food supply
• BevCanna’s TRACE line of products address issue through proprietary plant-based formula rich in iron, magnesium, calcium, potassium
• Company recently signed distribution agreement to reach target markets in New York, Chicago, California

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, helps consumers address nutrient deficiencies with its TRACE line of beverages and supplements. Sourced from deep within British Columbia’s Rocky Mountains, TRACE products are high in fulvic and humic minerals, providing an easily absorbed source of minerals such as iron, magnesium, calcium, potassium and other vital nutrients currently lacking in modern diets. Experts now agree that levels of soil minerals have depleted rapidly in recent decades due to large-scale industrial farming practices that use high amounts of chemical pesticides and artificial fertilizers (https://ibn.fm/GZXVX). Accordingly, these practices have produced a food supply that is less nutritious than decades ago, suggesting that it may not be possible to get enough nutrients solely from food – a problem that has entered mainstream consciousness in recent years. “Efforts to breed new varieties of crops that provide greater yield, pest resistance and climate adaptability have allowed crops to grow bigger and more rapidly,” reported Donald Davis, part of the University of Texas team of researchers that produced the report published in the Journal of the American College of Nutrition. “But their ability to manufacture or uptake nutrients has not kept pace with their rapid growth.” BevCanna addresses this issue by creating, manufacturing, and distributing mineral-rich beverages and supplements that resonate with a growing demographic of health-conscious consumers that understands the health risks of a mineral-poor diet. Sourced from deep within the Rocky Mountains of interior British Columbia, BevCanna’s TRACE line of beverages and supplements are formulated with a proprietary plant-based mineral formula rich in iron, magnesium, calcium and potassium, offering an easy way to supplement these critical minerals in the standard diet. “With demand for wellness-focused beverages rapidly increasing among U.S. consumers, this is the ideal time to introduce the TRACE brand to a whole new demographic,” said BevCanna President Melise Panetta (https://ibn.fm/2nkzo). As part of its expansion strategy to leverage its market leading position internationally in this rapidly growing market, BevCanna recently finalized an agreement with a leading U.S. brand and sales management firm to distribute the TRACE line of products to target markets in New York, Chicago and California. Along with these large urban centers, the company plans to take its products mainstream by expanding distribution to retailers across the sales spectrum to include independent specialty retailers and national big-box outlets. Based in the province of British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world-class HACCP-certified 40,000-square-foot manufacturing facility with an annual 210-million bottling capacity. In addition to its in-house brands, the company provides white-label services to numerous partners that include Keef – the #1 US cannabis beverage brand by units and dollars sold.* *BDSA For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) specializes in the use of ultra-high pressure technologies to innovate unexpected and potent solutions for a wide variety of industries, including biomarker and target discovery, forensics, counter-bioterror applications, improved quality and economics for biopharmaceuticals, and safer, more potent and more cost-effective, storage, dosing and absorption of nutrients, nutraceuticals, cosmeceuticals, agrochemicals for plants, and more
• Pressure BioSciences recently announced the development of extraordinarily effective dosing and delivery in uniform nanoemulsions of 30 to 60 nm droplets for the powerful antioxidant astaxanthin (“AsX”), and suitable for many other prospective nutraceuticals
• PBIO’s technology for nanoemulsions commands extremely high commercial appeal because of its ability to dramatically improve the entire sensory profile of many retail products, while simultaneously improving the economics for producers and/or consumers, and making medicines and nutraceuticals safer, more easily absorbed, and more bioavailable within targeted humans, animals and plants
• Their breakthrough achievement in AsX nanoemulsions is simply the demonstration gateway to the potential production of an enormous range of more bioavailable, higher quality fat-soluble vitamins, nutraceuticals and dietary supplements
• Preorders for its first dozen commercial nanoemulsion production systems are converting into PBIO’s powerful new leasing and royalty driven business model, with initial, solid incremental revenue expected in early 2022

The development of the oil-soluble antioxidant astaxanthin as an extremely fine and uniform nanoemulsion that easily disperses and effectively dissolves into water with intrinsic stability, was announced July 1, and launches a revolutionary new growth phase for life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) and its trademarked Ultra Shear Technology(TM) (“UST”) platform. Pressure BioSciences (also known as PBI) has developed its UST platform to apply ultra high pressure and intense shearing forces for the innovative production of a unique class of high-quality nanoemulsions that offer enormous new benefits in a wide variety of industries, including the nutraceuticals market, which is expected to powerfully leverage the benefit of the astaxanthin nanoemulsions development, into a plethora of other newly differentiated nutraceutical products. Astaxanthin, or AsX, is renowned as an antioxidant 6000 times more powerful than vitamin C that has been shown clinically to enhance the human body’s natural immune response, improve muscle endurance in exercise, support cardiovascular, brain and eye health, protect skin against UV damage, and beneficially modify cell signaling pathways that promote cancer cell death, according to Pressure BioSciences’ news release (https://ibn.fm/pKhEn). Because AsX is essentially water-insoluble, the body’s ability to absorb it rather than simply passing it through to excretion has been measured at typically less than 10 percent of the amount of ingested or topically applied compound. The nanoemulsion developed through the UST pressure and shearing IP has the potential to make AsX more easily and fully absorbed and bioavailable, and thus more effective with lower dosing and improved economics for the producer and/or the consumer.  Similar benefits for other carotenoids and a wide range of fat-soluble vitamins, nutraceuticals, dietary supplements are anticipated, and will extend into agrochemicals, cosmeceuticals and personal care products, and other industries. “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter” PBI Senior Research Scientist Gary B. Smejkal stated in the news release. “The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published.” Pressure BioSciences anticipates the use of its technology will make it possible for nutraceutical companies to exercise greater control over their dosing and find ways to lower their costs, which may in turn lower the costs for consumers. The pressure-shearing process also reduces the need for large amounts of added chemicals used currently in chemically produced nanoemulsions. “The global astaxanthin market size was estimated at USD 1.0 billion in 2019,” PBI President and CEO Richard T. Schumacher stated. “PBI is laser-focused on exploring the opportunities for our UST platform to profoundly alter the effectiveness and competitiveness of a great number of lucrative nutraceutical products. We have already begun discussions with prospective partners worldwide who are interested in using UST for production and commercialization of astaxanthin and other nutraceutical nanoemulsions.” The company has received pre-orders for 12 BaroShear K45 systems, the company’s first commercial application of its UST-based processing system, and expects to be able to fulfill the orders beginning late this year through a lease/royalty business model, which it expects to generate up to $3 million in incremental revenue in late 2021 and early 2022 (https://ibn.fm/AXJlp). Pressure BioSciences boasts an intellectual property portfolio already including more than 25 patents worldwide and is advancing rapidly towards inflections into significantly increased revenues and profitability. In addition to the nutraceuticals nanoemulsions market, the company’s primary focus includes pressure-based technology development of products for biomarker and target discovery, improved soil and plant biology, forensics, counter-bioterror applications, and improved quality and economics for biopharmaceuticals. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• SGTM transforms storm, hurricane waste into environmentally beneficial products that enhance, fortify the earth
• Company on solid growth trajectory with string of lucrative contracts awarded in recent months
• Clients include municipal governments, large commercial retailers including The Kroger Co, Circle K, Menards Inc. & Old Castle Lawn & Garden
• 2020 was record-breaking year, Q1-2021 results include QoQ increases of 16.7% in revenue and 8.6% in gross profit

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is on a growth trajectory with a lucrative string of large commercial contracts, a rock-solid growth strategy, and its unique business model rooted in sustainability (https://ibn.fm/wGE5L). SGTM’s synergistic business activities benefit the earth by diverting waste that otherwise would have burdened municipal landfills and transforming it into products that fortify and enhance the earth. Through its subsidiary National Storm Recovery LLC, SGTM is contracted to cut, haul and remove large volumes of clean wood debris that is then processed by Mulch Manufacturing Inc. – another SGTM wholly owned subsidiary – into organic gardening mulch and playground surfacing material. Besides allowing the company to eliminate disposal costs, this synergistic business model enables SGTM to receive mulch feedstock of high quality at a much lower net cost for maximum profits. “Getting paid for your feedstock in the mulch business is a recipe for success and great profit margins,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/FniIJ). “Storm recovery is a multibillion-dollar business, and we are prepared to help in any cleanup process.” SGTM broke records in 2020 with year-over-year increases of 794% in revenue and 4,817% in gross profit (https://ibn.fm/gLvEO), and the trend has continued for Q1-2021 with quarter-over-quarter increases of 16.7% in revenue and 8.6% in gross profit (https://ibn.fm/M6KvN). The company’s business model – unique to the industry – allows it to profit in two ways: first by offering paid services that enable it to acquire its feedstock and second by processing and selling the transformed products to large-scale commercial retailers such as The Kroger Co, Circle K, Menards Inc. & Old Castle Lawn & Garden. “This business combination has created an industry powerhouse, and with our combined strengths puts us in an ideal position to increase our sales and resulting margins as our combined operations benefit from the resulting vertical integration and economies of scale,” said Mulch Manufacturing CEO Ralph Spencer (https://ibn.fm/BlllT). SGTM’s centralized operations are based in Jacksonville, Florida across 26 acres with ample room to expand. With over 40 years of next-level experience with mulch manufacturing and tree management, SGTM’s leadership is committed to sustainably growing the company through a multi-pronged strategy that puts stewardship of the environment at the core of its mission. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/A0LxQ. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• The direct-sales space reported $40.1 billion in retail sales last year, an increase of 13.9% from 2019
• Successful direct-sales companies adapt quickly to a world with changing needs
• SHRG is working on multiple programs, expansion plans that will be unprecedented in the sector

The United States saw record high sales, sellers and customers in the direct-sales sector in 2020, according to the industry’s leading national trade association (https://ibn.fm/aymKA). That news bodes well for Sharing Services Global (OTCQB: SHRG), a publicly traded company specializing in the direct-sales sector. In its annual Growth & Outlook Study, the U.S. Direct Selling Association (“DSA”) reported exciting numbers for companies — and people — involved in the direct-sales space. According to the DSA, the direct-selling channel generated $40.1 billion in retail sales in 2020, an increase of 13.9% from 2019; the number of individuals selling products or services through a direct-selling business model also increased more than 13%, with 7.7 million U.S. entrepreneurs involved on either a full-time or part-time basis; and demand for products and services offered in the direct-selling sector grew as well, with 41.6 million preferred customers and discount buyers purchasing through the direct-sales channel. “America is forever changing, no more so than during the last year,” said DSA president Joseph N. Mariano. “Direct sellers have proven themselves time and again to be nimble microentrepreneurs, willing and able to serve their customers and communities within a changing environment. . . . Direct-selling companies also adapted quickly to a world with changing needs by empowering their independent sellers with the tools to serve their customers and fellow sellers — innovative technology, updated health and safety policies, and second-to-none business support.” Sharing Services Global can count itself among the savvy direct-sales companies that are nimble and quick to adapt to changing market needs. Earlier this year, the company announced a new brand identity for its two wholly owned subsidiaries: Elevacity Holdings LLC and Elevacity U.S. LLC, leading producers and distributors of nootropic, functional beverage products with a focus on health and wellness (https://ibn.fm/bPs2E). The new identity, branded The Happy Co., includes a complete redesign of both the consumer-facing website where The Happy Co. customers purchase products and the business-focused website that showcases the overarching opportunity. A few weeks later, the company announced its newest subsidiary, a travel company called Hapi Travel Destinations (https://ibn.fm/V3ZDJ). These announcements were made alongside news that SHRG was planning to expand into both Asia and Europe. The company is focused on establishing strategic plans to make the most of the opportunities provided in the growing direct-sales industry. “This is a very exciting time in the company, as we are working on multiple programs and expansion plans that will be unprecedented in this sector,” said Bo Short, CEO of Elevacity Holdings LLC and Elevacity International Holdings LLC. “I have been in direct selling for many years and have never seen an executive management team with such a long-term vision to reshape this industry and really serve its brand partners in this fashion. I’m excited and honored to be part of these new initiatives.” For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• HempFusion Wellness closed the acquisition of Sagely Naturals, a women-centric CBD company, for an initial consideration of US$25 million in cash and stock payments
• The acquisition is expected to benefit both parties in various ways, including by increasing HempFusion’s revenue and providing access to Sagely’s extensive distribution footprint
• On its part, Sagely will benefit from HempFusion’s regulatory compliance, which will help in the introduction of ingestible CBD products
• HempFusion is looking forward to driving shareholder value through continued growth both domestically and internationally with its expanding family of brands

In fulfillment of a merger agreement announced in late May, Denver-based leading health and wellness company HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 800) completed the acquisition of premier women-centric CBD brand Sagely Enterprises Inc. (“Sagely Naturals”) on July 7 (https://ibn.fm/qIzoy). The purchase, which made Sagely Naturals a wholly owned subsidiary of HempFusion Wellness, is expected to benefit both parties. Boasting an extensive retail distribution footprint of 14,000+ stores in the United States, Sagely Naturals is the third most successful brand, leading CBD topicals brand, and largest women-founded CBD company in the industry. This market position is reflected in its financials for the fiscal year 2020, in which it reported net revenue of over $4.19 million. The now wholly owned subsidiary provides HempFusion with immediate distribution to up to 14,000 additional stores as well as a significant increase in revenue. In fact, when combined with the closing of APCNA Holdings LLC’s (“Apothecanna”) purchase agreement, announced May 17, HempFusion’s 2020 revenue will more than triple. Both acquisitions further offer the opportunity to expand this revenue well into the future. In an interview with Proactive (https://ibn.fm/xfGSM), HempFusion CEO Jason Mitchell, N.D., noted that while Sagely Naturals does not offer ingestible CBD products at the moment, HempFusion’s focus on being regulatorily compliant will allow it to install a completely new ingestible program for them. This will provide an opportunity to introduce ingestible CBD products in up to 14,000 stores. “So, we are going to give them near-immediate expansion into new products they haven’t had previously,” said Mitchell. HempFusion’s significant investment into regulatory compliance will help solidify Sagely Natural’s leadership position in the CBD industry. HempFusion has also included Sagely Naturals on its Novel Foods Application Dossier with the United Kingdom’s Regulatory Food Safety Agency to aid in future expansion into Europe. Additionally, as both companies have complementary product offerings that do not directly compete, the acquisition offers substantial cross-platform opportunities through each of their respective distribution channels. “Integration has been well underway over the past several weeks, and we look forward to driving shareholder value through continued growth in 2021 and 2022 both domestically and internationally with our expanding family of brands,” stated Mitchell in a press release. HempFusion closed the acquisition for an initial consideration of US$25 million, of which $2 million was paid in cash (subject to adjustment for Sagely Naturals’ cash and working capital), and the balance was satisfied by the issuance of more than 22.5 million common HempFusion shares. You can find a comprehensive description of the terms of the acquisition in the press release. In the Proactive interview, Mitchell held that M&A remains a vital part of the company’s future. Thus, the recent acquisition of Sagely Naturals “is certainly not going to be our last.” For more information, visit the company’s website at www.HempFusion.com/corporate-information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/CBDHF

Date: July 21-23, 2021  Virtual Event Companies and professionals from the biocompatibility, toxicology, materials engineering, and related medical fields are invited to attend the Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference being held on July 21-23, 2021. Industry leaders and regulatory authorities will share presentations discussing compliant design and commercialization evaluation processes for medical device professionals to develop safe testing strategies. This online streaming conference is a great opportunity for you to meet and collaborate with industry professionals to ensure your products meet biological safety requirements as per the global safety standards. The event will be hosted on the dynamic Q1 Productions virtual platform that customizes the user experience by connecting attendees with their peers. Attendees will get answers to their queries while the dynamic formats ensure that participants enjoy the virtual experience. Industry leaders attending the conference will discuss safety measures and safety standards to meet the design requirements for the commercial market. The event is sponsored by WuXi AppTec Medical Device Testing, a world-class solution provider offering integrated, testing solutions that enable clients to develop strategies and safe life-changing healthcare solutions for patients and caregivers. The conference media partner is BioMedWire (“BMW”), a technology-driven communications platform. Important points to be covered at the Conference:

• Designing proper biological evaluation plans in a risk management process
• Discussion on the criteria, selection, and common measures for risk-based biological evaluation planning
• Ways to refine E&L Testing performance and efficiency
• Overcoming biocompatibility and toxicology challenges of the world markets
• Partnering with lab-testing services for better navigation, communication and to overcome the lack of uniformity
• Defining testing criteria for ethylene oxide residual testing
• Optimizing biocompatibility analysis in response to manufacturing alterations

The 2^nd Annual Medical Device Biocompatibility & Toxicology Risk assessment Conference offers insights and valuable information that allows you to test planning with in-depth analysis of regulatory requirements to ensure product reliability & patient safety. Q1 productions have a Virtual Event Guide & FAQ forum for a better user experience. The mobile app Q1 Events offers all networking experiences of the virtual platform for a seamless experience. For more information about the event, please visit https://ibn.fm/uRrPo.

• XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
• This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
• The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
• XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023

For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy. XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase safety in schools, medical centers and other government services and facilitating rapid airport, border and cruise ship testing to minimize travel risk. Summer is usually the high travel season. With the Covid-19 outbreak, there has been a surge in demand for reliable and rapid testing. XPhyto acknowledges this demand and plans on capitalizing on it with its Covid-ID Lab kit, the fastest PCR system in the world, according to XPhyto’s Chief Executive Officer (“CEO”), Hugh Rogers. “Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes,” said Hugh Rogers, the CEO and director of XPhyto. “We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach,” he added (https://ibn.fm/sgnkA). XPhyto Therapeutics Corp. is a bioscience accelerator focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its profile currently falls under three broad categories: diagnostics, drug delivery, and drug development (https://ibn.fm/GJn0r). For drug development, XPhyto focuses on four late-stage neurology therapeutics within clinical development, along with two other psychedelic medicine programs. For its drug delivery program, XPhyto has a platform technology already in place. It is designed to develop innovative, cost-effective transdermal and oral dissolvable formulations of hybrid-generic, generic and new active pharmaceutical ingredients. XPhyto’s diagnostics lead product is the rapid POC COVID-19 RT-PCR diagnostic test, which launched in Europe in April 2021. The goal for the entire program is to develop real-time ultra-low-cost infectious disease biosensors and making tests, particularly Covid-19 PCR tests, fast and affordable. With the growing requirement for PCR tests for travelling, XPhyto recognizes the tremendous potential for rapid PCR checks from a commercial standpoint. “Rapid, reliable and decentralized PCR tests are exactly what the market needs right now; precisely because incidence rates are falling and therefore sample numbers are decreasing,” noted Michael Kretzer, the CEO of Max Pharma, XPhyto’s distribution partner and pharmaceutical wholesaler (https://ibn.fm/dDOjN). “There will be areas of application where rapid, reliable, and universally recognized results are always required. Accordingly, we see a specialized and sustainable opportunity for the Covid-ID and anticipate a steep order volume uptake in the near future,” he added. Covid-ID Lab represents a significant shift from conventional PCR testing models. Typically, samples collected are shipped to large centralized and automated labs for processing. This has been known to not only take time but also be expensive (https://ibn.fm/4RMhK). XPhyto seeks to address this with its decentralized testing model. It projects that it will yield faster results, more versatile test center options and, most importantly, cost-effectiveness at lower testing volumes. The deployment of the 1000 Covid-ID Lab test kits marks the start of a short trial period for integrating and evaluating XPhyto’s new PCR test system. The entire process is designed so that sample processing will occur directly at the sample collection site. The data collected will allow the company to launch the product successfully in other locations across Europe. XPhyto continues to innovate and grow its three key sectors. With the deployment of its Covid-ID Lab, the company aims at capitalizing on the rapid test market that is projected to reach $39.1 billion by 2023, representing a compound annual growth rate (“CAGR”) of 8.9% between 2021 and 2023. The two other aspects of XPhyto’s diagnostic pipeline include the Peptide biosensor for infectious diseases and the Peptide biosensor for oral health, both of which are still in their design and development stages. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• Avricore Health Inc. is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues
• The company’s wholly owned subsidiary, HealthTab, offers fast, accurate and cost-effective point-of-care screening
• Its current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR); HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19
• The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, to offer high quality, low-cost screening tests
• In June 2021, Avricore announced its master agreement to pilot its HealthTab platform for diabetes management in select Shoppers Drug Mart pharmacies
• Avricore’s ultimate aim is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacy

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab(TM) (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. HealthTab HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform. The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (“RWD”) sets and third-party app integration through API. Agreement with Shoppers Drug Mart In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2(TM) analyzers provided by Abbott Rapid Diagnostics. Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes. Near Term Goals Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage. Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies. Market Outlook In 2020, the global point-of-care testing (“POCT”) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (“CAGR”) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19. The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection. Management Team Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion. Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs. David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia. Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia. Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF